EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer (Q44067889)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer |
scientific article |
Statements
1 reference
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer (English)
1 reference
A Hamilton
1 reference
L Biganzoli
1 reference
R Coleman
1 reference
L Mauriac
1 reference
P Hennebert
1 reference
A Awada
1 reference
M Nooij
1 reference
L Beex
1 reference
M Piccart
1 reference
I Van Hoorebeeck
1 reference
P Bruning
1 reference
D de Valeriola
1 reference
1 June 2002
1 reference
1 reference
Identifiers
1 reference